论文部分内容阅读
目的研究颅内肿瘤诊断中血清和脑脊液β2-微球蛋白(β2-microglobulin,β2-MG)测定的临床意义。方法用免疫比浊法测定75例颅内肿瘤患者和24例对照组血清和脑脊液β2-MG含量。颅内肿瘤组分为良、恶性两组。运用方差分析或秩和检验方法对对照组与颅内肿瘤患者检测结果及良、恶性颅内肿瘤患者检测结果之间进行统计分析。结果恶性肿瘤组的脑脊液和血清β2-MG含量明显高于对照组(P<0.01和P<0.05),有统计学意义。良性肿瘤组脑脊液β2-MG含量明显高于对照组(P<0.01),但血清β2-MG含量与对照组比较无统计学意义(P=0.375)。病理Ⅰ级和Ⅲ级之间比较有统计学意义(P<0.01)。结论β2-MG是良好的肿瘤生化标志物。同时测定血清和脑脊液β2-MG含量有助于颅内良、恶性瘤肿瘤的诊断和鉴别,脑脊液β2-MG还可以辅助诊断肿瘤的部位,有助于临床医生设计治疗方案。
Objective To study the clinical significance of determination of β2-microglobulin (β2-MG) in serum and cerebrospinal fluid in the diagnosis of intracranial tumors. Methods Serum and cerebrospinal fluid levels of β2-MG were measured by immunoturbidimetry in 75 patients with intracranial tumors and 24 controls. Intracranial tumor components were benign and malignant in both groups. The variance analysis or rank sum test was used to analyze the test results between the control group and intracranial tumor patients and the test results of patients with benign and malignant intracranial tumors. Results The content of β2-MG in cerebrospinal fluid and serum in malignant tumor group was significantly higher than that in control group (P <0.01 and P <0.05). The content of β2-MG in cerebrospinal fluid in benign tumor group was significantly higher than that in control group (P <0.01), but the serum β2-MG content was not significantly different from that in control group (P = 0.375). Pathological grade Ⅰ and Ⅲ were statistically significant (P <0.01). Conclusion β2-MG is a good tumor biochemical markers. Simultaneous determination of serum and cerebrospinal fluid β2-MG content is helpful for the diagnosis and differential diagnosis of benign and malignant intracranial tumors. Cerebrospinal fluid β2-MG can also assist in the diagnosis of tumor sites and help clinicians to design treatment plans.